Kymera Therapeutics (KYMR)
(Delayed Data from NSDQ)
$31.20 USD
-0.62 (-1.95%)
Updated Jun 18, 2024 04:00 PM ET
After-Market: $31.15 -0.05 (-0.16%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum F VGM
Price, Consensus and EPS Surprise
KYMR 31.20 -0.62(-1.95%)
Will KYMR be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for KYMR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KYMR
Zacks Industry Outlook Highlights BioMarin, Blueprint Medicines, Immunovant, Kymera and Ligand
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
KYMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know
Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Other News for KYMR
Cracking The Code: Understanding Analyst Reviews For Kymera Therapeutics
Buy Rating Affirmed for Kymera Therapeutics’ KT-333 on Strong Clinical Data and Therapeutic Potential
Wall Street Analysts Are Bullish on Top Healthcare Picks
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
Kymera Therapeutics presents clinical data from Phase 1 trial of KT-333